Find → Understand → Decide
Azacitidine
Discovery priority: LOW · POSSIBLE / INVESTIGATE
Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.
Why investigate?
Why stranded (event context): inadequate public evidence
Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established
Company/trial failed before biology? UNKNOWN
Biology implicated: UNCLEAR · Failure context: UNKNOWN
MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.
Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN
Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.
Existing buyer gates
Human Signal: UNKNOWN
Cheap Truth: UNKNOWN
Clean Rights: UNKNOWN
Market Pull: UNKNOWN
No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.
Evidence timeline
2026-08-17 · trial:NCT07387354
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
FDA requested significant changes to the study protocol
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "53e9450d612b10eefeeb1f7ab2d724a4d1ef4235aee4a413c325ec9efe75b2ab",
"metadata": {
"complete": false,
"content_hash": "4cabd429cb884ebeb9efe5893ed7344dfcca71cd4076988989429865aef061a0",
"failed": false,
"last_checked": 1790026983.0118148,
"last_success": 1790026983.0118148,
"live_verified": true,
"scope": "AREA[OverallStatus]WITHDRAWN AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "4cabd429cb884ebeb9efe5893ed7344dfcca71cd4076988989429865aef061a0",
"raw_path": "research/obz7_sources/4cabd429cb884ebeb9efe5893ed7344dfcca71cd4076988989429865aef061a0.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]WITHDRAWN AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT07387354"
}2026-08-25 · trial:NCT06514261
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
Other - Pending amendment for study expansion.
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "c248e409aa0f51e7d176edb1405679d81a7a07ec1cdec6606944fec7cf495f0c",
"metadata": {
"complete": false,
"content_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
"failed": false,
"last_checked": 1790026985.182528,
"last_success": 1790026985.182528,
"live_verified": true,
"scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
"raw_path": "research/obz7_sources/2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT06514261"
}2026-08-26 · trial:NCT07388563
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
New recruitment on hold for a protocol design amendment/modification.
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "86c2b545b2f3fca4ed3035cc92a7f95468538fb884245a27da2f396a0f4cfd6e",
"metadata": {
"complete": false,
"content_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
"failed": false,
"last_checked": 1790026985.182528,
"last_success": 1790026985.182528,
"live_verified": true,
"scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
"raw_path": "research/obz7_sources/2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT07388563"
}Freshness is claim-specific
Fetching an old filing today does not establish current ownership or program status.
pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
clinicaltrials · STALE · AREA[OverallStatus]WITHDRAWN AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:03.011815+00:00
clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:05.182528+00:00
clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:05.182528+00:00
Registry observations (5)
NCT07387354 · WITHDRAWN · PHASE1, PHASE2 · Myelodysplastic Syndromes; MDS; Myelodysplastic Syndrome, Unclassifiable; Hematologic Diseases; Bone Marrow Disease; Myeloproliferative Neoplasm · Trial sponsor Thomas Jefferson University
Reported aliases: Vidaza; 5-Azacytidine. Identity, treatment role and exposure require review.
NCT07388563 · SUSPENDED · PHASE1 · Lymphoma, T Cell, Peripheral; T-cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Monomorphic Epitheliotropic Intestinal T-cell Lymphoma; Adult T-cell Leukemia/Lymphoma · Trial sponsor National Cancer Institute (NCI)
Reported aliases: None. Identity, treatment role and exposure require review.
NCT06514261 · SUSPENDED · PHASE1 · Acute Myeloid Leukemia · Trial sponsor National Cancer Institute (NCI)
Reported aliases: 5 AZC; 5-AC; 5-Azacitidine; 5-Azacytidine; 5-AZC; Azacytidine; Azacytidine, 5-; Ladakamycin; Mylosar; U-18496; Vidaza. Identity, treatment role and exposure require review.
NCT01541280 · COMPLETED · PHASE2 · Acute Myeloid Leukemia; Myelodysplastic Syndrome · Trial sponsor Nantes University Hospital
Reported aliases: None. Identity, treatment role and exposure require review.
NCT03588078 · COMPLETED · PHASE1, PHASE2 · Myelodysplastic Syndrome With Gene Mutation; Acute Myeloid Leukemia With Gene Mutations; Myeloproliferative Neoplasm; Chronic Myelomonocytic Leukemia · Trial sponsor Groupe Francophone des Myelodysplasies
Reported aliases: Mylosar; Vidaza. Identity, treatment role and exposure require review.